Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW to Establish a Venue for Discussions to Review Policies for OTC Switching of Lifestyle Disease Treatments
December 21, 2012
-
REGULATORY Osaka’s Healthcare Plan Highlights Differences in Definition of “Frequent Deliveries”
December 21, 2012
-
REGULATORY CSIMC Recommends New Rules on Reducing Prices of Long-Listed Drugs
December 21, 2012
-
REGULATORY MHLW to Revise and Consider Legislation of Ethical Guidelines for Clinical Research
December 20, 2012
-
REGULATORY Pharmaceutical Industry Welcomes Incoming Abe Administration
December 19, 2012
-
BUSINESS Takeda Faces Generic Entry for Candesartan in US
December 18, 2012
-
BUSINESS Pfizer Specialty Care Chief Hopeful about Japan Vaccine Market, Novel RA Treatment
December 17, 2012
-
BUSINESS Elmed Eisai, Kobayashi Kako Get Their Allegra Generics Listed
December 14, 2012
-
BUSINESS Zydus to Build New Plant in India for Japan-Bound Generics
December 13, 2012
-
REGULATORY Strategy Council Proposes Revamped Framework to Oversee Entire Life Innovation Budgets
December 12, 2012
-
BUSINESS Mochida Revving Up Collaboration Efforts in Biosimilars
December 11, 2012
-
REGULATORY Long-Listed Products Not Granted Premium Should Be Exempted from New Rule: FPMAJ’s Kamoya
December 10, 2012
-
BUSINESS Actavis Eyes 3 Monoclonal Antibodies for Entry into Japanese Biosimilar Market: EVP
December 10, 2012
-
BUSINESS With Spiriva Combination Product in PIII, BI Not Fear Competition in COPD Market: Chairman Barner
December 7, 2012
-
REGULATORY CSIMC Subcommittee Agrees on Introduction of New Price-Cut Rule for Long-Listed Products
December 6, 2012
-
ORGANIZATION Drug Costs Should Be Basically Borne by Patients under Compassionate Use System: JPMA’s Kuwahara
December 5, 2012
-
ORGANIZATION 80 Medical Institutions Submit Comprehensive Agreements on Info Disclosure in Response to JPMA Transparency GLs
December 4, 2012
-
REGULATORY MHLW to Conduct Field Study for Japanese Version of “Compassionate Use” System
December 3, 2012
-
BUSINESS Fast-growing Plavix Could Become Japan’s No. 1 Ethical Drug by Next Year
December 3, 2012
-
BUSINESS CMIC MPSS to Offer Comprehensive Region-Wide CSO Service for Long-Listed Drugs
November 30, 2012
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…